{
    "nct_id": "NCT05192122",
    "official_title": "Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): a Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance (HEME-20)",
    "inclusion_criteria": "* ECOG Performance Status equal to or less than 2 within 30 days prior to registration\n* Revised International Staging System (R-ISS) I,2 or 3\n* Patients with multiple myeloma as defined by IMWG\n* Received at least 2 years of post ASCT maintenance (patients may have received any number of prior lines of therapy).\n* Maintenance therapy is defined as any anti-myeloma therapy initiated after ASCT to prevent disease recurrence and prolong time in remission (i.e., lenalidomide, bortezomib, RVD, etc.)\n* Disease response is VGPR or CR at the time of enrollment as defined by IMWG criteria.\n* Patients or their legally authorized representative must be able to understand and be willing to sign a voluntary informed consent form and agree to compliance with the protocol schedule; with the knowledge that they may withdraw consent at any time without impact on future medical care\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with plasma cell leukemia, AL amyloidosis or Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin (POEMS) syndrome\n* Prior organ transplant or condition requiring immunosuppressive therapy\n* Prior allogeneic hematopoietic cell transplant\n* Treatment with any investigational drug within 30 days prior to enrollment\n* Unable to sign an informed consent or their legally authorized represnetative",
    "miscellaneous_criteria": ""
}